The Herceptin Biosimilars Market is experiencing remarkable growth as healthcare systems worldwide increasingly adopt cost-effective biologic alternatives for the treatment of HER2-positive cancers. Herceptin biosimilars are highly similar versions of trastuzumab, a monoclonal antibody that targets the human epidermal growth factor receptor 2 (HER2), which is overexpressed in certain breast and...